Sign In
Buy ASMB
$25.55
+0.330 (+1.31%)
At Close: Jul 24, 2026
Assembly Biosciences Announces Effective Date of Reverse Stock Split
08:00am, Thursday, 08'th Feb 2024
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –
Assembly Biosciences Provides Anticipated Development Milestones for 2024
08:00am, Thursday, 04'th Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral d
5 Penny Stocks With Big Black Friday Stock Market News
09:50am, Friday, 24'th Nov 2023
Penny stocks, defined as stocks trading under $5 per share, offer investors the allure of exponential growth. As an inherently volatile market sector, penny stocks can rapidly surge on positive news,
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 10'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral d
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
08:00am, Wednesday, 08'th Nov 2023
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRA
Why Are Stocks Down Today?
11:17am, Tuesday, 17'th Oct 2023
Stocks are down today and investors wondering why are in the right place as we have all the details they need to know about on Tuesday! The big reason that stocks are down today has to do with the lat
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
10:59am, Tuesday, 17'th Oct 2023
Assembly Biosciences (NASDAQ: ASMB ) stock is taking off on Tuesday after announcing a massive collaboration with Gilead Sciences (NASDAQ: GILD ). According to a press release, these two companies hav
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
08:00am, Wednesday, 11'th Oct 2023
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company's interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLO
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
08:00am, Monday, 02'nd Oct 2023
− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected –
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
04:05pm, Tuesday, 19'th Sep 2023
-- Two oral presentations and one poster will feature new data from the Company's hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist pro
-- First presentation of preclinical data describing the activity, pharmacokinetics and safety profile of ABI-5366, supporting planned clinical entry in 1H 2024 -- SOUTH SAN FRANCISCO, Calif., July 17
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
04:05pm, Tuesday, 23'rd May 2023
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral di
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
08:05pm, Wednesday, 22'nd Mar 2023 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeti
Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board
07:00am, Tuesday, 17'th Jan 2023
BOSTON--(BUSINESS WIRE)--Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Camero
TEVA Shares Rise on Broad Support for Opioids Settlement
03:03pm, Tuesday, 10'th Jan 2023 Zacks Investment Research
With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.
